ReviewIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Pancreatic exocrine insufficiency beyond pancreatitis.
Review in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic exocrine insufficiency (PEI) occurs when the amount of digestive enzymes released from the pancreas in response to a meal is insufficient or the enzymes are prematurely inactivated, thus resulting in maldigestion. The chief reasons for PEI include loss of pancreatic parenchyma, obstruction of the main pancreatic duct, reduced stimulation and pancreatic enzyme inactivation. Loss of pancreatic parenchyma in chronic pancreatitis and after an episode of severe acute necrotizing pancreatitis are the most common causes for PEI. However, PEI is an important cause for malabsorption in many other diseases beyond pancreatitis. These include pancreatic tumors, pancreas resection, cystic fibrosis, diabetes and inflammatory bowel disease. Though the pancreas secretes lipase, amylase and proteases, which are all required for digestion, it is only lipase insufficiency that is clinically important. Fat maldigestion occurs when lipase secretion falls to below 10% of normal. This threshold is defined as severe PEI and is a definite indication for pancreatic enzyme replacement therapy (PERT). In this review, we shall discuss about conditions, other than pancreatitis, which cause PEI, and understand the possible mechanisms by which they cause PEI. We shall also discuss whether the addition of PERT will benefit patient management in such conditions.
Indexed as
Identifiers
41272334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.